JP2012524114A - Ｍｅｋ阻害剤としてのヘテロ環式化合物 - Google Patents
Ｍｅｋ阻害剤としてのヘテロ環式化合物 Download PDFInfo
- Publication number
- JP2012524114A JP2012524114A JP2012506346A JP2012506346A JP2012524114A JP 2012524114 A JP2012524114 A JP 2012524114A JP 2012506346 A JP2012506346 A JP 2012506346A JP 2012506346 A JP2012506346 A JP 2012506346A JP 2012524114 A JP2012524114 A JP 2012524114A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- phenylamino
- oxo
- tetrahydro
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *Nc(cccc1)c1F Chemical compound *Nc(cccc1)c1F 0.000 description 3
- SVMVUFLWYDXQDB-UHFFFAOYSA-N C=CCC1(CC1)S(N(C(C(N1c(ccc(Br)c2)c2F)=C2F)=C(CCC3)N3C2=O)C1=O)(=O)=O Chemical compound C=CCC1(CC1)S(N(C(C(N1c(ccc(Br)c2)c2F)=C2F)=C(CCC3)N3C2=O)C1=O)(=O)=O SVMVUFLWYDXQDB-UHFFFAOYSA-N 0.000 description 1
- IJEKFDVCHBYBIR-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1N(C2=O)S(C3(CC=C)CC3)(=O)=O)=O)=C1N2c(ccc(I)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1N(C2=O)S(C3(CC=C)CC3)(=O)=O)=O)=C1N2c(ccc(I)c1)c1F IJEKFDVCHBYBIR-UHFFFAOYSA-N 0.000 description 1
- TYBMKZJERZGOMG-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1NS(C2(CC(CO)O)CC2)(=O)=O)=O)=C1Nc(ccc(Br)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1NS(C2(CC(CO)O)CC2)(=O)=O)=O)=C1Nc(ccc(Br)c1)c1F TYBMKZJERZGOMG-UHFFFAOYSA-N 0.000 description 1
- PTCSHTILRISHIZ-UHFFFAOYSA-N CC1(C)OC(CNS(NC(C(Nc(ccc(Br)c2)c2F)=C2F)=C(CCC3)N3C2=O)(=O)=O)CO1 Chemical compound CC1(C)OC(CNS(NC(C(Nc(ccc(Br)c2)c2F)=C2F)=C(CCC3)N3C2=O)(=O)=O)CO1 PTCSHTILRISHIZ-UHFFFAOYSA-N 0.000 description 1
- XALFJQYNKDYEOO-UHFFFAOYSA-N CCOC(C(C(Cl)=C1Cl)=C(CCC2)N2C1=O)=O Chemical compound CCOC(C(C(Cl)=C1Cl)=C(CCC2)N2C1=O)=O XALFJQYNKDYEOO-UHFFFAOYSA-N 0.000 description 1
- IBDYMBPCXTZASG-UHFFFAOYSA-N COCOCC(C(C(Nc(c(F)c1)ccc1Br)=C1F)=C(CCC2)N2C1=O)O Chemical compound COCOCC(C(C(Nc(c(F)c1)ccc1Br)=C1F)=C(CCC2)N2C1=O)O IBDYMBPCXTZASG-UHFFFAOYSA-N 0.000 description 1
- LRPYUBGEOIENQC-UHFFFAOYSA-N CONC(C(C(Nc(c(F)c1)ccc1Br)=C1F)=C(CCC2)N2C1=O)=O Chemical compound CONC(C(C(Nc(c(F)c1)ccc1Br)=C1F)=C(CCC2)N2C1=O)=O LRPYUBGEOIENQC-UHFFFAOYSA-N 0.000 description 1
- ZZFKFVUOBJANDU-UHFFFAOYSA-N O=C(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)NOCC1CC1 Chemical compound O=C(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)NOCC1CC1 ZZFKFVUOBJANDU-UHFFFAOYSA-N 0.000 description 1
- UDUJLFLJBHPZEL-UHFFFAOYSA-N O=C(C(C(Nc1ccc(C(F)(F)F)cc1F)=C1)=C(CCC2)N2C1=O)NOCC1CC1 Chemical compound O=C(C(C(Nc1ccc(C(F)(F)F)cc1F)=C1)=C(CCC2)N2C1=O)NOCC1CC1 UDUJLFLJBHPZEL-UHFFFAOYSA-N 0.000 description 1
- QYNNUVCJVUGKSD-UHFFFAOYSA-N O=C(NC(C1=C2)=C(CCC3)N3C2=O)N1c(c(F)c1)ccc1Br Chemical compound O=C(NC(C1=C2)=C(CCC3)N3C2=O)N1c(c(F)c1)ccc1Br QYNNUVCJVUGKSD-UHFFFAOYSA-N 0.000 description 1
- QDODGBZMNFTXSZ-UHFFFAOYSA-N OC(C(C(Nc(c(F)c1)ccc1I)=C1)=C(CCC2)N2C1=O)=O Chemical compound OC(C(C(Nc(c(F)c1)ccc1I)=C1)=C(CCC2)N2C1=O)=O QDODGBZMNFTXSZ-UHFFFAOYSA-N 0.000 description 1
- AAUTYWDJHZRYMP-UHFFFAOYSA-N OCCONC(C(C(Nc(c(F)c1)ccc1Br)=C1)=C(CCCC2)N2C1=O)=O Chemical compound OCCONC(C(C(Nc(c(F)c1)ccc1Br)=C1)=C(CCCC2)N2C1=O)=O AAUTYWDJHZRYMP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/054717 WO2010121646A1 (en) | 2009-04-21 | 2009-04-21 | Heterocyclic compounds as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2012524114A true JP2012524114A (ja) | 2012-10-11 |
Family
ID=43010696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012506346A Pending JP2012524114A (ja) | 2009-04-21 | 2009-04-21 | Ｍｅｋ阻害剤としてのヘテロ環式化合物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2421612A1 (pt) |
| JP (1) | JP2012524114A (pt) |
| KR (1) | KR20120028882A (pt) |
| CN (1) | CN102458580A (pt) |
| AU (1) | AU2009344690A1 (pt) |
| BR (1) | BRPI0925050A2 (pt) |
| CA (1) | CA2761108A1 (pt) |
| EA (1) | EA201101533A1 (pt) |
| MX (1) | MX2011011083A (pt) |
| WO (1) | WO2010121646A1 (pt) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013510118A (ja) * | 2009-11-04 | 2013-03-21 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| JP2016503391A (ja) * | 2012-10-19 | 2016-02-04 | ノバルティス アーゲー | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022057B2 (en) | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| CA2838029A1 (en) * | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
| GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
| US9428499B2 (en) | 2012-03-14 | 2016-08-30 | Lupin Limited | Heterocyclyl compounds as MEK inhibitors |
| WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| CN108640916A (zh) * | 2018-06-07 | 2018-10-12 | 广东药科大学 | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 |
| CN109761977B (zh) * | 2019-03-05 | 2020-07-17 | 江西省药品检验检测研究院 | 一种黄精生物碱c及其制备方法与应用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| US8022057B2 (en) * | 2007-11-12 | 2011-09-20 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
-
2009
- 2009-04-21 KR KR1020117027486A patent/KR20120028882A/ko not_active Application Discontinuation
- 2009-04-21 BR BRPI0925050-6A patent/BRPI0925050A2/pt not_active IP Right Cessation
- 2009-04-21 AU AU2009344690A patent/AU2009344690A1/en not_active Abandoned
- 2009-04-21 WO PCT/EP2009/054717 patent/WO2010121646A1/en active Application Filing
- 2009-04-21 CA CA2761108A patent/CA2761108A1/en not_active Abandoned
- 2009-04-21 EP EP09779322A patent/EP2421612A1/en not_active Withdrawn
- 2009-04-21 CN CN2009801598607A patent/CN102458580A/zh active Pending
- 2009-04-21 MX MX2011011083A patent/MX2011011083A/es not_active Application Discontinuation
- 2009-04-21 JP JP2012506346A patent/JP2012524114A/ja active Pending
- 2009-04-21 EA EA201101533A patent/EA201101533A1/ru unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013510118A (ja) * | 2009-11-04 | 2013-03-21 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| JP2016503391A (ja) * | 2012-10-19 | 2016-02-04 | ノバルティス アーゲー | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
| JP2018135399A (ja) * | 2012-10-19 | 2018-08-30 | ノバルティス アーゲー | Ｍｅｋ阻害剤の調製およびｍｅｋ阻害剤を含む製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009344690A1 (en) | 2011-10-27 |
| EA201101533A1 (ru) | 2012-05-30 |
| CN102458580A (zh) | 2012-05-16 |
| CA2761108A1 (en) | 2010-10-28 |
| MX2011011083A (es) | 2011-11-04 |
| WO2010121646A1 (en) | 2010-10-28 |
| KR20120028882A (ko) | 2012-03-23 |
| EP2421612A1 (en) | 2012-02-29 |
| BRPI0925050A2 (pt) | 2015-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012524114A (ja) | Ｍｅｋ阻害剤としてのヘテロ環式化合物 | |
| JP5466767B2 (ja) | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 | |
| EP1900729A1 (en) | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors | |
| NZ588069A (en) | Hydroxamate-based inhibitors of deacetylases b | |
| EP3426244B1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| US20090275606A1 (en) | Heterocyclic Compounds as MEK Inhibitors | |
| JP5456908B2 (ja) | ヘテロ環式スルホンアミド誘導体 | |
| WO2015022664A1 (en) | Compounds and compositions as inhibitors of mek | |
| JP2014517004A (ja) | 複素環スルホンアミド誘導体 | |
| US8470878B2 (en) | Heterocyclic sulfonamide derivatives | |
| WO2015022663A1 (en) | Compounds and compositions as inhibitors of mek | |
| Subramanya | 2, Patent Application Publication to, Pub. No.: US 2009/0275606 A1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20130813 |